Evidence map›Paper›PMID 26283733›Full record

ArticleMolecular and cellular biology2015

Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder.

WooJin Kim, Erin Zekas, Robert Lodge, Delia Susan-Resiga, Edwidge Marcinkiewicz, Rachid Essalmani, Koichiro Mihara, Rithwik Ramachandran, Eugene Asahchop, Benjamin Gelman and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Reply to Spek and Duitman.American journal of respiratory and critical care medicine · 2023
    Article
  8. PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?American journal of respiratory and critical care medicine · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. GPR37 is processed in the N-terminal ectodomain by ADAM10 and furin.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

WooJin KimLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
Erin ZekasLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
Robert LodgeLaboratory of Human Retrovirology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
Delia Susan-ResigaLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
Edwidge MarcinkiewiczLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
Rachid EssalmaniLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
Koichiro MiharaInflammation Research Network, Snyder Institute for Chronic Diseases, and Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Rithwik RamachandranInflammation Research Network, Snyder Institute for Chronic Diseases, and Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Eugene AsahchopDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Benjamin GelmanDepartments of Pathology and Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Éric A CohenLaboratory of Human Retrovirology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada.
Christopher PowerDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Morley D HollenbergInflammation Research Network, Snyder Institute for Chronic Diseases, and Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Nabil G SeidahLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada seidahn@ircm.qc.ca.
Université de Montréal · CAUniversity of Calgary · CAMontreal Clinical Research Institute · CAUniversity of Alberta · CAThe University of Texas Medical Branch at Galveston · US

Funding

Texas NeuroAIDS Research CenterU24MH100930 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2023
$12.1M
Canadian Institutes of Health ResearchNIMH NIH HHS U24 MH100930NIMH NIH HHS U24MH100930
6 · The paper itself

Abstract

The proprotein convertases (PCs) furin, PC5, PACE4, and PC7 cleave secretory proteins after basic residues, including the HIV envelope glycoprotein (gp160) and Vpr. We evaluated the abundance of PC mRNAs in postmortem brains of individuals exhibiting HIV-associated neurocognitive disorder (HAND), likely driven by neuroinflammation and neurotoxic HIV proteins (e.g., envelope and Vpr). Concomitant with increased inflammation-related gene expression (interleukin-1β [IL-1β]), the mRNA levels of the above PCs are significantly increased, together with those of the proteinase-activated receptor 1 (PAR1), an inflammation-associated receptor that is cleaved by thrombin at ProArg41↓ (where the down arrow indicates the cleavage location), and potentially by PCs at Arg41XXXXArg46↓. The latter motif in PAR1, but not its R46A mutant, drives its interactions with PCs. Indeed, PAR1 upregulation leads to the inhibition of membrane-bound furin, PC5B, and PC7 and inhibits gp160 processing and HIV infectivity. Additionally, a proximity ligation assay revealed that furin and PC7 interact with PAR1. Reciprocally, increased furin expression reduces the plasma membrane abundance of PAR1 by trapping it in the trans-Golgi network. Furthermore, soluble PC5A/PACE4 can target/disarm cell surface PAR1 through cleavage at Arg46↓. PACE4/PC5A decreased calcium mobilization induced by thrombin stimulation. Our data reveal a new PC-PAR1-interaction pathway, which offsets the effects of HIV-induced neuroinflammation, viral infection, and potentially the development of HAND.

Indexed as

Protein Interaction MapsAmino Acid SequenceAnimalsBrainCell LineFurinGene Expression RegulationHIV-1HIV Envelope Protein gp160HIV InfectionsHost-Pathogen InteractionsHumansInflammationMiceMolecular Sequence DataNeurocognitive DisordersFurinHIV Envelope Protein gp160PCSK6 protein, humanPCSK7 protein, humanProprotein Convertase 5Proprotein ConvertasesReceptor, PAR-1RNA, MessengerSerine EndopeptidasesSubtilisinsThrombin

Identifiers

PMID26283733
PMCPMC4589605
OpenAlexW2226996271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.